Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT06447623RecruitingPhase 3
Apatinib plus CDK4/6 inhibitor for first-line HR+/HER2- SNF4 breast cancer
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07118202Recruiting
TheraBionic device for advanced liver cancer
This trial tests a device called TheraBionic P1 for people with advanced liver cancer that has not responded to other treatments. It may be an option if you have tried at least two prior therapies or cannot take standard treatments.
Bay City, MichiganAges 22 years+ - NCT06885385RecruitingPhase 2
Study of JS207 with or without JS015 and chemo for colorectal cancer
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07670013RecruitingPhase 2
SKB264 and glecirasib for advanced KRAS G12C lung cancer
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Hangzhou, ZhejiangAges 18–75 - NCT07171996Recruiting
Radioactive seed therapy for spinal tumors
This trial tests a procedure where tiny radioactive seeds are placed into spinal tumors to relieve pain and control growth. It is for people with cancer that has spread to the bone and who are able to undergo the procedure safely.
Jinan, ShandongAges 18–55 - NCT07111520RecruitingPhase 1/Phase 2
Combination treatment for advanced lung cancer
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06703398RecruitingPhase 2
Study of GC101 TIL for advanced melanoma
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
BeijingAges 18–75 - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT07539311RecruitingPhase 2
Testing Rina-S for Advanced Gastrointestinal Cancers
This study tests a new drug called Rina-S in people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have spread or cannot be surgically removed. The drug is designed to help slow or stop cancer growth in people whose cancer has gotten worse despite recent treatment.
Grand Rapids, MichiganAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+ - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT06885034RecruitingPhase 1/Phase 2
Testing a New Drug for Advanced Colon, Rectal, or Pancreatic Cancer
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
Los Alamitos, CaliforniaAges 18 years+ - NCT07297667RecruitingPhase 1
CAR T-cell therapy for GPNMB-positive solid tumours
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called GPNMB found on some tumour types. It's for people with advanced alveolar soft part sarcoma, certain kidney cancers, or triple-negative breast cancer that hasn't responded to standard treatments.
Calgary, AlbertaAges 15 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06613100RecruitingPhase 1
Xaluritamig before prostate surgery for high-risk prostate cancer
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
San Francisco, CaliforniaAges 18 years+ - NCT07230691Recruiting
Study of amivantamab for advanced EGFR-mutated lung cancer
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
GrazAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.